Advertisement
Screener

LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) Impairment of Intangible Assets (Excluding Goodwill)

2.4 / 5 stars · 43/91 Roast Me

LIGAND PHARMACEUTICALS INCORPORATED Impairment of Intangible Assets (Excluding Goodwill)

LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Impairment of Intangible Assets (Excluding Goodwill) of $6.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-02-27

  • LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for the quarter ending 2025-12-31 was $6.20M, a 51.85% increase year-over-year.
  • LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for the quarter ending 2025-09-30 was $0.00.
  • LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
  • LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for the quarter ending 2025-03-31 was $0.00.
  • LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for fiscal 2025 was $6.20M, a 79.73% decline from fiscal 2024.
  • LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for fiscal 2024 was $30.57M.
  • LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for fiscal 2023 was $0.00.
  • LIGAND PHARMACEUTICALS INCORPORATED impairment of intangible assets (excluding goodwill) for fiscal 2022 was $0.00.
Period endImpairment of Intangible Assets (Excluding Goodwill) 3 monthImpairment of Intangible Assets (Excluding Goodwill) 6 monthImpairment of Intangible Assets (Excluding Goodwill) 9 monthImpairment of Intangible Assets (Excluding Goodwill) 12 month
2025-12-31$6.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$6.20M
derived: sum of 2 quarters · filed 2026-02-27
$6.20M
derived: sum of 3 quarters · filed 2026-02-27
$6.20M
10-K · filed 2026-02-27
2025-09-30$0.00
10-Q · filed 2025-11-07
$0.00
derived: sum of 2 quarters · filed 2025-11-07
$0.00
10-Q · filed 2025-11-07
$4.08M
derived: sum of 4 quarters · filed 2026-02-27
2025-06-30$0.00
10-Q · filed 2025-08-08
$0.00
10-Q · filed 2025-08-08
$4.08M
derived: sum of 3 quarters · filed 2026-02-27
$4.08M
derived: sum of 4 quarters · filed 2026-02-27
2025-03-31$0.00
derived: 10-K 12 month − 3 quarters · filed 2026-02-27
$4.08M
derived: sum of 2 quarters · filed 2026-02-27
$4.08M
derived: sum of 3 quarters · filed 2026-02-27
$30.57M
derived: sum of 4 quarters · filed 2026-02-27
2024-12-31$4.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$4.08M
derived: sum of 2 quarters · filed 2026-02-27
$30.57M
derived: sum of 3 quarters · filed 2026-02-27
$30.57M
10-K · filed 2026-02-27
2024-09-30$0.00
10-Q · filed 2025-11-07
$26.49M
derived: sum of 2 quarters · filed 2025-11-07
$26.49M
10-Q · filed 2025-11-07
2024-06-30$26.49M
10-Q · filed 2025-08-08
$26.49M
10-Q · filed 2025-08-08
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$0.00
derived: sum of 2 quarters · filed 2026-02-27
$0.00
derived: sum of 3 quarters · filed 2026-02-27
$0.00
10-K · filed 2026-02-27
2023-09-30$0.00
10-Q · filed 2024-11-08
$0.00
derived: sum of 2 quarters · filed 2024-11-08
$0.00
10-Q · filed 2024-11-08
2023-06-30$0.00
10-Q · filed 2024-08-07
$0.00
10-Q · filed 2024-08-07
2022-12-31$0.00
10-K · filed 2025-02-28
2010-12-31$2.80M
10-K · filed 2013-03-14